Device Exchange in HeartMate II Recipients: Long-Term Outcomes and Risk of Thrombosis Recurrence

Successful long-term use of the HeartMate II (HM II) left ventricular assist device has become commonplace but may be complicated by mechanical failure, infection, or thrombosis necessitating device exchange (DE). A subcostal approach to device exchange with motor exchange only is less traumatic, but long-term outcomes have not been reported. A retrospective chart review of all patients who required HM II to HM II device exchange at our institution was conducted. Of the 232 HM II patients implanted between January 2008 and July 2013, 28 required 36 device exchanges during a follow-up of 33.72 ± 17.25 months. The Kaplan–Meier 1 year survival was 63% for sternotomy exchanges and 100% for subcostal exchanges. Twenty-one exchanges were performed for initial or recurring device thrombosis. Although there was no difference in the risk of subsequent thrombosis after subcostal versus sternotomy exchange, the overall risk of recurring device thrombosis after device exchange for the same was high (31%). HM II device exchange via the subcostal approach has excellent short- and long-term outcomes. Device exchange performed for thrombosis is associated with a high recurrence risk irrespective of surgical approach

[1]  F. Pagani,et al.  Device exchange after primary left ventricular assist device implantation: indications and outcomes. , 2013, The Annals of thoracic surgery.

[2]  N. Smedira,et al.  Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. , 2013, The Annals of thoracic surgery.

[3]  Nir Uriel,et al.  Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. , 2012, Journal of the American College of Cardiology.

[4]  G. Ewald,et al.  Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy , 2012, Circulation. Heart failure.

[5]  N. Uriel,et al.  Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. , 2010, Journal of the American College of Cardiology.

[6]  S. Russell,et al.  Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[8]  W. Cohn,et al.  Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device. , 2008, The Annals of thoracic surgery.

[9]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[10]  Nir Uriel,et al.  Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  N. Uriel,et al.  Continuous-flow left ventricular assist device exchange: clinical outcomes. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  G. Ewald,et al.  Unexpected abrupt increase in left ventricular assist device thrombosis. , 2014, The New England journal of medicine.

[13]  Sean Pinney,et al.  Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.